{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:49:47Z","timestamp":1760237387069,"version":"build-2065373602"},"reference-count":78,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BPD\/76225\/2011; SFRH\/BD\/87488\/2012; SFRH\/BD\/70715\/2010"],"award-info":[{"award-number":["SFRH\/BPD\/76225\/2011; SFRH\/BD\/87488\/2012; SFRH\/BD\/70715\/2010"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gilead Sciences Portugal","award":["PGG\/015\/2016 and PGG\/02\/2015"],"award-info":[{"award-number":["PGG\/015\/2016 and PGG\/02\/2015"]}]},{"name":"Aga Khan Development Network (AKDN) \u2013 Portugal Collaborative Research Network in Portuguese speaking countries in Africa","award":["3328216"],"award-info":[{"award-number":["3328216"]}]},{"name":"European &amp; Developing Countries Clinical Trials Partnership (EDCTP), UE","award":["RIA2016MC-1615"],"award-info":[{"award-number":["RIA2016MC-1615"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Development of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority for the HIV-1 vaccine field. Envelope glycoproteins from non-B-non-C HIV-1clades have not been fully explored as components of a vaccine. We produced Vaccinia viruses expressing a truncated version of gp120 (gp120t) from HIV-1 clades CRF02_AG, H, J, B, and C and examined their immunogenicity in mice and rabbits. Mice primed with the recombinant Vaccinia viruses and boosted with the homologous gp120t or C2V3C3 polypeptides developed antibodies that bind potently to homologous and heterologous envelope glycoproteins. Notably, a subset of mice immunized with the CRF02_AG-based envelope immunogens developed a cross-reactive neutralizing response against tier 2 HIV-1 Env-pseudoviruses and primary isolates. Rabbits vaccinated with the CRF02_AG-based envelope immunogens also generated potent binding antibodies, and one animal elicited antibodies that neutralized almost all (13 of 16, 81.3%) tier 2 HIV-1 isolates tested. Overall, the results suggest that the novel CRF02_AG-based envelope immunogens and prime-boost immunization strategy elicit the type of immune responses required for a preventive HIV-1 vaccine.<\/jats:p>","DOI":"10.3390\/vaccines8020171","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T05:59:47Z","timestamp":1586325587000},"page":"171","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies"],"prefix":"10.3390","volume":"8","author":[{"given":"Rita","family":"Calado","sequence":"first","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5736-9138","authenticated-orcid":false,"given":"Joana","family":"Duarte","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"given":"Pedro","family":"Borrego","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"given":"Jos\u00e9 Maria","family":"Marcelino","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisboa, Portugal"},{"name":"Centro de Investiga\u00e7\u00e3o Interdisciplinar Egas Moniz (CiiEM), Instituto Universit\u00e1rio Egas Moniz, 2829-511 Monte de Caparica, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2022-8921","authenticated-orcid":false,"given":"In\u00eas","family":"B\u00e1rtolo","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"given":"Francisco","family":"Martin","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"given":"In\u00eas","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"given":"Silvia","family":"Almeida","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, 1649-02 Lisboa, Portugal"},{"name":"Post-Graduate Program in Infectious Diseases, and Department of Social Medicine, Center of Health Sciences, Federal University of Espirito Santo, Vit\u00f3ria 29075-910, Brazil"}]},{"given":"Lu\u00eds","family":"Gra\u00e7a","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, 1649-02 Lisboa, Portugal"}]},{"given":"Jorge","family":"V\u00edtor","sequence":"additional","affiliation":[{"name":"Biochemistry and Human Biology Dept, Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-419X","authenticated-orcid":false,"given":"Frederico","family":"Aires da Silva","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina Veterin\u00e1ria, Universidade de Lisboa, 1300-477 Lisboa, Portugal"}]},{"given":"In\u00eas","family":"Dias","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina Veterin\u00e1ria, Universidade de Lisboa, 1300-477 Lisboa, Portugal"}]},{"given":"Belmira","family":"Carrapi\u00e7o","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina Veterin\u00e1ria, Universidade de Lisboa, 1300-477 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0176-5585","authenticated-orcid":false,"given":"Nuno","family":"Taveira","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o do Medicamento (iMed.ULisboa), Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisboa, Portugal"},{"name":"Centro de Investiga\u00e7\u00e3o Interdisciplinar Egas Moniz (CiiEM), Instituto Universit\u00e1rio Egas Moniz, 2829-511 Monte de Caparica, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2016.05.011","article-title":"New concepts in HIV-1 vaccine development","volume":"41","author":"Stephenson","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1126\/science.1254990","article-title":"AIDS\/HIV. Host controls of HIV neutralizing antibodies","volume":"344","author":"Haynes","year":"2014","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"aac4223","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"Sanders","year":"2015","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-091014-090749","article-title":"Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design","volume":"67","author":"Sadanand","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cuevas, J.M., Geller, R., Garijo, R., Lopez-Aldeguer, J., and Sanjuan, R. (2015). Extremely High Mutation Rate of HIV-1 In Vivo. PLoS Biol., 13.","DOI":"10.1371\/journal.pbio.1002251"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1241144","article-title":"Antibodies in HIV-1 vaccine development and therapy","volume":"341","author":"Klein","year":"2013","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1586\/14787210.2013.825443","article-title":"The origin and molecular epidemiology of HIV","volume":"11","author":"Peeters","year":"2013","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: Understanding nature\u2019s pathways","volume":"254","author":"Mascola","year":"2013","journal-title":"Immunol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.virol.2012.10.004","article-title":"Broadly neutralizing antibodies against HIV-1: Templates for a vaccine","volume":"435","author":"Sanders","year":"2013","journal-title":"Virology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/COH.0000000000000442","article-title":"Neutralization tiers of HIV-1","volume":"13","author":"Montefiori","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/imr.12511","article-title":"Use of broadly neutralizing antibodies for HIV-1 prevention","volume":"275","author":"Pegu","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.it.2014.08.007","article-title":"Antibody B cell responses in HIV-1 infection","volume":"35","author":"Mouquet","year":"2014","journal-title":"Trends Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Corti, D., Langedijk, J.P., Hinz, A., Seaman, M.S., Vanzetta, F., Fernandez-Rodriguez, B.M., Silacci, C., Pinna, D., Jarrossay, D., and Balla-Jhagjhoorsingh, S. (2010). Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0008805"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Watkins, J.D., Siddappa, N.B., Lakhashe, S.K., Humbert, M., Sholukh, A., Hemashettar, G., Wong, Y.L., Yoon, J.K., Wang, W., and Novembre, F.J. (2011). An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018207"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1128\/JVI.02658-10","article-title":"Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop","volume":"85","author":"Moore","year":"2011","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1128\/jvi.66.12.7538-7542.1992","article-title":"Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody","volume":"66","author":"Gorny","year":"1992","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1089\/aid.2004.20.1254","article-title":"The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1","volume":"20","author":"Zhong","year":"2004","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cerutti, N., Loredo-Varela, J.L., Caillat, C., and Weissenhorn, W. (2017). Antigp41 membrane proximal external region antibodies and the art of using the membrane for neutralization. Curr. Opin. HIV AIDS.","DOI":"10.1097\/COH.0000000000000364"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1126\/science.aae0474","article-title":"Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody","volume":"352","author":"Kong","year":"2016","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41591-018-0042-6","article-title":"Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1","volume":"24","author":"Xu","year":"2018","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/nsmb.1861","article-title":"Conserved structural elements in the V3 crown of HIV-1 gp120","volume":"17","author":"Jiang","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13232","DOI":"10.1128\/JVI.78.23.13232-13252.2004","article-title":"Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies","volume":"78","author":"Binley","year":"2004","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"Pitisuttithum","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Pitisuttithum","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"310rv317","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"Corey","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gray, G.E., Huang, Y., Grunenberg, N., Laher, F., Roux, S., Andersen-Nissen, E., De Rosa, S.C., Flach, B., Randhawa, A.K., and Jensen, R. (2019). Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci. transl. med., 11.","DOI":"10.1126\/scitranslmed.aax1880"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0168-1702(02)00200-9","article-title":"Immunization of rabbits with a modified vaccinia Ankara recombinant virus bearing the HIV envelope antigen on its outer membrane","volume":"90","author":"Barchichat","year":"2002","journal-title":"Virus Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8644","DOI":"10.1128\/JVI.00853-16","article-title":"Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1\/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization","volume":"90","author":"Townsley","year":"2016","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12429","DOI":"10.1128\/JVI.01102-10","article-title":"Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy","volume":"84","author":"Marcelino","year":"2010","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Narayan, K.M., Agrawal, N., Du, S.X., Muranaka, J.E., Bauer, K., Leaman, D.P., Phung, P., Limoli, K., Chen, H., and Boenig, R.I. (2013). Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0052732"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Quinnan, G.V., Onabajo, O., Zhang, P., Yan, L., Mattapallil, J.J., Zhang, Z., Dong, M., Lu, M., Montefiori, D., and LaBranche, C. (2014). Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098060"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Klasse, P.J., LaBranche, C.C., Ketas, T.J., Ozorowski, G., Cupo, A., Pugach, P., Ringe, R.P., Golabek, M., van Gils, M.J., and Guttman, M. (2016). Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. PLoS Pathog, 12.","DOI":"10.1371\/journal.ppat.1005864"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10993","DOI":"10.1128\/JVI.01403-16","article-title":"Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response","volume":"90","author":"Powell","year":"2016","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.it.2016.01.007","article-title":"HIV-1 Envelope Trimer Design and Immunization Strategies to Induce Broadly Neutralizing Antibodies","volume":"37","author":"Moore","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.immuni.2019.10.008","article-title":"Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability","volume":"51","author":"Dubrovskaya","year":"2019","journal-title":"Immunity"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Francica, J.R., Laga, R., Lynn, G.M., Muzikova, G., Androvic, L., Aussedat, B., Walkowicz, W.E., Padhan, K., Ramirez-Valdez, R.A., and Parks, R. (2019). Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. PLoS Biol., 17.","DOI":"10.1371\/journal.pbio.3000328"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kibler, K.V., Asbach, B., Perdiguero, B., Garcia-Arriaza, J., Yates, N.L., Parks, R., Stanfield-Oakley, S., Ferrari, G., Montefiori, D.C., and Tomaras, G.D. (2019). Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. J. Virol., 93.","DOI":"10.1128\/JVI.01513-18"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.cell.2019.04.012","article-title":"Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance","volume":"177","author":"Cirelli","year":"2019","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature23301","article-title":"Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows","volume":"548","author":"Sok","year":"2017","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1089\/aid.2016.0084","article-title":"Rare HIV-1 Subtype J Genomes and a New H\/U\/CRF02_AG Recombinant Genome Suggests an Ancient Origin of HIV-1 in Angola","volume":"32","author":"Bartolo","year":"2016","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/QAD.0b013e32835edc1d","article-title":"An ancestral HIV-2\/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity","volume":"27","author":"Borrego","year":"2013","journal-title":"AIDS"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/molbev\/msp259","article-title":"SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building","volume":"27","author":"Gouy","year":"2010","journal-title":"Mol. Biol. Evol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3851\/IMP1996","article-title":"Baseline susceptibility of primary HIV-2 to entry inhibitors","volume":"17","author":"Borrego","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nbt1371","article-title":"Bioinformatics prediction of HIV coreceptor usage","volume":"25","author":"Lengauer","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1093\/nar\/18.14.4285","article-title":"New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins","volume":"18","author":"Davison","year":"1990","journal-title":"Nucleic Acids Res."},{"key":"ref_47","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10903","DOI":"10.1128\/JVI.74.23.10903-10910.2000","article-title":"Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1","volume":"74","author":"Rose","year":"2000","journal-title":"J. Virol."},{"key":"ref_49","unstructured":"Arthos, J. (2018, July 05). Purification of HIV Envelope Protein. Available online: http:\/\/www.aidsreagent.org\/pdf_images\/4126_001.pdf."},{"key":"ref_50","unstructured":"Laboratory, M. (2018, May 19). Protocol for Heat-Inactivation of Serum and Plasma Samples, Available online: http:\/\/www.hiv.lanl.gov\/content\/nab-reference-strains\/html\/Protocol-for-Heat-Inactivation-of-Serum-and-Plasma-Samples_Jan2016.pdf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1128\/JVI.02853-13","article-title":"Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"88","author":"deCamp","year":"2014","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Bailer","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"D1133","DOI":"10.1093\/nar\/gkt1083","article-title":"bNAber: Database of broadly neutralizing HIV antibodies","volume":"42","author":"Eroshkin","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jviromet.2010.05.008","article-title":"Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells","volume":"168","author":"Finzi","year":"2010","journal-title":"J Virol Methods"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1128\/JVI.00718-12","article-title":"Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion","volume":"87","author":"Alam","year":"2013","journal-title":"J. virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1097\/QAD.0000000000001177","article-title":"Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies","volume":"30","author":"Burger","year":"2016","journal-title":"AIDS"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181a24906","article-title":"HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique","volume":"51","author":"Bartolo","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/CVI.00597-15","article-title":"Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques","volume":"23","author":"Thippeshappa","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kibler, K.V., Asbach, B., Perdiguero, B., Garcia-Arriaza, J., Yates, N.L., Parks, R., Stanfield-Oakley, S., Ferrari, G., Montefiori, D.C., and Tomaras, G.D. (2019). Correction for Kibler et al., \"Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC\". J. virol., 93.","DOI":"10.1128\/JVI.00968-19"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.meegid.2008.05.003","article-title":"Highly divergent subtypes and new recombinant forms prevail in the HIV\/AIDS epidemic in Angola: New insights into the origins of the AIDS pandemic","volume":"9","author":"Bartolo","year":"2009","journal-title":"Infect. Genet. Evol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.meegid.2016.08.009","article-title":"On the contribution of Angola to the initial spread of HIV-1","volume":"46","author":"Varanda","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Barroso, H., Borrego, P., Bartolo, I., Marcelino, J.M., Familia, C., Quintas, A., and Taveira, N. (2011). Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0014548"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1089\/aid.2005.21.58","article-title":"Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies","volume":"21","author":"Kim","year":"2005","journal-title":"AIDS Res Hum Retrovir."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1128\/JVI.80.3.1414-1426.2006","article-title":"Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants","volume":"80","author":"Li","year":"2006","journal-title":"J. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2006.10.032","article-title":"A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120","volume":"360","author":"Beddows","year":"2007","journal-title":"Virology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"Flynn","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1128\/JVI.02252-09","article-title":"Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs","volume":"84","author":"Nkolola","year":"2010","journal-title":"J. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Yusim, K.D.B., Koup, R., Korber, B.T.M., de Boer, R., Moore, J.P., Watkins, D.I., Brander, C., Haynes, B.F., and Walker, B.D. (2015). HIV Molecular Immunology.","DOI":"10.2172\/1169681"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1128\/JCM.37.5.1356-1360.1999","article-title":"Discrimination of subtype B and non-subtype B strains of human immunodeficiency virus type 1 by serotyping: Correlation with genotyping","volume":"37","author":"Murphy","year":"1999","journal-title":"J Clin Microbiol"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.str.2009.09.012","article-title":"Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: Implications for design of V3-based immunogens","volume":"17","author":"Burke","year":"2009","journal-title":"Structure"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1089\/aid.2008.0188","article-title":"Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies","volume":"25","author":"Cardozo","year":"2009","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1128\/JVI.02905-14","article-title":"Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope","volume":"89","author":"Doores","year":"2015","journal-title":"J. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"236ra263","DOI":"10.1126\/scitranslmed.3008104","article-title":"Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV","volume":"6","author":"Sok","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/protein\/3.5.433","article-title":"Sequence differences between glycosylated and non-glycosylated Asn-X-Thr\/Ser acceptor sites: Implications for protein engineering","volume":"3","author":"Gavel","year":"1990","journal-title":"Protein Eng."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.1021\/bi972217k","article-title":"The amino acid following an asn-X-Ser\/Thr sequon is an important determinant of N-linked core glycosylation efficiency","volume":"37","author":"Mellquist","year":"1998","journal-title":"Biochemistry"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/2\/171\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:16:08Z","timestamp":1760174168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/2\/171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":78,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["vaccines8020171"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8020171","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2020,4,7]]}}}